TNFSF10: a promising prognostic biomarker and therapeutic target for immunotherapy in testicular germ cell tumors

Background Testicular germ cell tumors (TGCTs) are malignant neoplasms with a poor prognosis, and the absence of reliable biomarkers for patient stratification and diagnosis presents a significant challenge. Methods We employed an integrated analysis of Single-Cell RNA-Sequencing and TCGA data to evaluate TNFSF10 as a potential biomarker for prognosis and immunotherapy in TGCTs. Results Our findings revealed that aberrant TNFSF10 expression was significantly associated with patient survival outcomes. Silencing TNFSF10 inhibited the proliferation, migration, and invasion of TGCT cells, highlighting its role in tumor progression. Moreover, TNFSF10 expression was closely correlated with various components of the tumor microenvironment, suggesting its involvement in both the biological behavior of TGCTs and their response to treatment. Conclusion TNFSF10 emerges as a promising diagnostic and prognostic biomarker for stratification and targeted therapy in TGCTs, offering new prospects for personalized treatment strategies.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-04-28
DOI
https://doi.org/10.3389/fimmu.2026.1761075
Primary Topic
Testicular diseases and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TNFSF10: a promising prognostic biomarker and therapeutic target for immunotherapy in testicular germ cell tumors

Shanshan Lv, Guangmin Liu, Kongrong Xu, Liqing Fan et al.
Frontiers in Immunology
Testicular diseases and treatments
article

TNFSF10: a promising prognostic biomarker and therapeutic target for immunotherapy in testicular germ cell tumors

Shanshan Lv, Guangmin Liu, Kongrong Xu, Liqing Fan, Jian Cao, Lei Xue, Lin Du, Shusheng Zhang, Zhizhong Liu
article en

Abstract

Background Testicular germ cell tumors (TGCTs) are malignant neoplasms with a poor prognosis, and the absence of reliable biomarkers for patient stratification and diagnosis presents a significant challenge. Methods We employed an integrated analysis of Single-Cell RNA-Sequencing and TCGA data to evaluate TNFSF10 as a potential biomarker for prognosis and immunotherapy in TGCTs. Results Our findings revealed that aberrant TNFSF10 expression was significantly associated with patient survival outcomes. Silencing TNFSF10 inhibited the proliferation, migration, and invasion of TGCT cells, highlighting its role in tumor progression. Moreover, TNFSF10 expression was closely correlated with various components of the tumor microenvironment, suggesting its involvement in both the biological behavior of TGCTs and their response to treatment. Conclusion TNFSF10 emerges as a promising diagnostic and prognostic biomarker for stratification and targeted therapy in TGCTs, offering new prospects for personalized treatment strategies.

Frontiers in ImmunologyVol. 17
Central South University (CN), Wenzhou Medical University (CN), Reproductive & Genetic Hospital CITIC-Xiangya (CN), The First Hospital of Changsha (CN), Hunan Cancer Hospital (CN), National Engineering Research Center of Human Stem Cells (CN), Guangxi Maternal and Child Health Hospital (CN), Dongyang People's Hospital (CN), Xiangya Hospital Central South University (CN)
No poverty
Openalex Percentile: Top 13%
Testicular diseases and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.